Is ChromaDex Corporation a good investment? ChromaDex Corporation (CDXC) is currently trading at 7.87 USD. Market analysts have a consensus price target of 7.96 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 382.00. This high multiple suggests investors have priced in significant future growth expectations.
No, it does not currently pay a dividend.
ChromaDex Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
| Split Date | Split Ratio to 1 |
|---|---|
| April 13, 2016 | 1:3 |
Community Discussion